SHARx, LLC.

11/14/2025

What is a laser on an employee, and why should you care?

It's a secret provision in your stop-loss that sets a higher deductible for a high-cost claimant.

Result: The insurer is protected, and you face unpredictable costs.

The fix? Manage the risk driver: high-cost prescription drugs.

Read our blog to get the full breakdown and see why strategic sourcing is the best defense against being lasered: https://sharxplan.com/what-is-a-laser-and-why-does-it-matter/

11/11/2025

SHARx provides employers with a streamlined, powerful solution for effective cost control of specialty and high-cost medications. Our program works to mitigate the financial burden imposed by these necessary drugs, ensuring that employees maintain uninterrupted access to lifesaving medications, and the company's budget remains protected.

11/11/2025

Today, we pause to honor the enduring strength, profound sacrifice, and deep commitment of our nation's veterans. Their bravery remains a constant source of motivation for us all.

11/07/2025

11/07/2025

Who benefits when drug distributors control the point of care? (Hint: It’s not your health plan.)

A new consolidation trend is inflating specialty drug costs. Wholesalers are acquiring physician practices to influence prescribing decisions toward higher-margin products.

Demand clarity. Demand control.

Read our latest blog to learn more and see how SHARx is challenging this opaque system.

🔗 https://sharxplan.com/the-next-hidden-middleman-how-wholesalers-are-tightening-their-grip-on-drug-access/

11/06/2025

Meet Jessica Burkard -

Jessica is an essential force in keeping mail order operations running smoothly. Her deep expertise and unwavering willingness to lend a hand make a tremendous impact on our team’s success.

With a consistently positive attitude, she embraces each day’s challenges with grace and determination. Jessica is a forward thinker, a reliable teammate, and a true asset to SHARx.

We’re incredibly grateful for everything she does!

11/04/2025

SHARx steps in to deliver medications, further instilling that critical care for chronic conditions or autoimmune therapies should never be gated by financial hardship. We exist to ensure members can focus on healing, not crippling debt.

11/03/2025

ERISA: More Than an Acronym. It's Your Legal Duty.

Did you know your PBM could be compromising your compliance? Traditional contracts are designed to hide fees, leaving you—the Plan Fiduciary—vulnerable to lawsuits.

In our latest blog, we explain the connection between PBM transparency and meeting the highest standard of care under federal law.

Read the full blog post to learn:
- What ERISA is and who qualifies for its protection.
- Why full transparency is now essential for compliance.
- How SHARx works to strengthen your fiduciary integrity.

🔗 https://sharxplan.com/beyond-compliance-how-sharx-strengthens-fiduciary-integrity-under-erisa/

10/31/2025

This Halloween, we're helping employers and members unburden themselves from the truly scary part of healthcare: out-of-control prescription costs! Don't let high-cost and specialty medications be the monster under your bed.

At SHARx, we use the power of procurement and compassionate care to fight the good fight and ensure everyone has affordable access to the medicine they need.

Wishing you a safe, healthy, and frightfully fun night—without the healthcare scares!

10/28/2025

Our partners trust SHARx because we make complex sourcing simple — without sacrificing transparency or care. That’s the SHARx difference.

Read how we’re raising the standard for specialty drug programs: https://sharxplan.com/not-all-specialty-drug-programs-are-created-equal/

10/24/2025

'𝐎𝐧 𝐭𝐡𝐞 𝐑𝐚𝐝𝐚𝐫' | 7th Edition is live!

Drug pricing reform, domestic manufacturing, and the evolution of PBMs continue to dominate headlines. This edition breaks down the complex forces shaping employer healthcare costs and the broader pharmaceutical landscape.

In this issue:

✔ FDA launches pilot program to boost U.S.-made generics
✔ Scientists discover a way to cut drug production costs by 60%
✔ PBMs plan to drop Stelara reference drugs amid a biosimilar pricing war
✔ Anti-PBM legislation forces new plan strategies
✔ TrumpRx and DTC sales reshape the path to lower prices

Check out the seventh edition: 🔗 https://sharxplan.com/on-the-radar-7th-edition/

A bi-weekly installment where SHARx shares timely, research-based insights that track what’s happening in the world of pharmacy benefit management, healthcare policy, and drug pricing—so you don’t have to dig through the noise.

10/23/2025

Your prescription benefit spending is likely funding PBM profits, not your people. Traditional models are built on hidden fees, spread pricing, and zero transparency.

Self-funded employers are reclaiming control. By eliminating pharmaceutical waste, you gain fresh financial flexibility.

Don't just manage costs, strategically reinvest them to enhance retention and elevate your employer brand.

Read our guide to see how SHARx can enable a significant upgrade to your benefits plan: https://sharxplan.com/how-to-reinvest-prescription-spend-waste-into-employee-centric-initiatives/